Shots:
- Vanda Pharmaceuticals has initiated the Thetis study assessing Nereus (tradipitant) vs PBO for the prevention of vomiting in pts receiving GLP-1 receptor agonist therapies
- The Thetis study will assess the proportion of pts free from vomiting episodes as the 1EP, with Vanda expecting topline results by Q4’26 & noting that additional data may be required before NDA approval
- In a P-II study, tradipitant showed reduced vomiting vs PBO (1EP; 29.3% vs 58.6%) & vomiting with significant nausea (22.4% vs 48.3%) after a 1 mg Wegovy injection
Ref: PRnewswire | Image: Vanda | Press Release
Related News: Vanda Pharmaceuticals Reports the US FDA’s Approval of Bysanti (Milsaperidone) for Acute Bipolar I Disorder & Schizophrenia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
